Opinion

Video

Management of Recurrent C Difficile Infections in the Future

Key Takeaways

  • Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
  • Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
SHOW MORE

Paul Feuerstadt, MD, FACG, AGAF, discusses how the management of recurrent Clostridioides difficile infections is evolving toward more targeted approaches, including microbiome-based therapies like fecal microbiota transplantation, newer antibiotics such as fidaxomicin, and emerging preventive strategies focusing on microbiome restoration and preservation.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
EHA 2025 Congress Recap | Image Credit: Venngage
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo